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Background
In the past years, once-daily (QD) dosing of antiretroviral
combination therapy has become an increasingly availa-
ble treatment option for HIV-1+ patients.
Methods
Open label study in which HIV-1+ patients treated with
SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-
RNA-PCR < 50 copies/ml were switched to SAQ/
RTV(2000/100 mg QD) with unchanged NRTI-backbone.
CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and
metabolic parameters were compared.
Summary of results
17 patients (15 male, 42 years), median CD4 456 ± 139/
μl were included so far. The median follow-up time is 4
months. The HIV-RNA-PCR remained <50 copies/ml for
all patients. Fasting metabolic parameters remained
unchanged. The SAQ AUC 0–12 h were significantly
higher when given QD vs. BID (median 29,400 vs. 18,500
ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC
was lower for RTV when given QD vs. BID (7,400 vs.
11,700 ng*h/ml; p = 0.02).
Conclusion
In this ongoing study SAQ/RTV (2000/100 mg QD) was
well tolerated and demonstrated higher SAQ and lower
RTV drug levels as compared to the BID dosing schedule.
(Table 1 and Figure 1.)
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Table 1: 
baseline month 3 p-value
Glucose [mg/dl] 91 ± 12 91 ± 10 0.9
Triglycerides [mg/dl] 178 ± 106 161 ± 96 0.7
Total chol. [mg/dl] 199 ± 43 206 ± 46 0.8
HDL chol. [mg/dl] 43 ± 9 44 ± 8 0.8
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SAQ drug level BID vs. QD Figure 1
SAQ drug level BID vs. QD.